Hospital
VHS of Phoenix INC
VHS of Phoenix INC was paid $52.47M by Medicaid between Jan 2018 and Dec 2024, across 283 billing codes. Its largest line is 99285, emergency room visit (most serious) — 22% of everything it billed.
33Billing provider infoVHS OF PHOENIX INC
PHOENIX, AZ 85015
PHOENIX, AZ 85015
33aNPI1477537363assigned 12/03/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$52.47M
24GClaims1,232,129
24DCodes billed283
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#11 of 78
Median peer was paid$12.21M
This provider vs. median4.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 244,632 | $9.81M | |
| 2019 | 211,271 | $9.15M | |
| 2020 | 173,134 | $6.85M | |
| 2021 | 170,248 | $7.03M | |
| 2022 | 159,527 | $7.20M | |
| 2023 | 145,515 | $6.55M | |
| 2024incomplete | 127,802 | $5.89M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 22% | 37,339 | 33,772 | $11.30M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 52,992 | 48,843 | $10.68M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 61,471 | 56,993 | $9.91M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.7% | 7,018 | 6,620 | $4.54M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.7% | 6,880 | 6,426 | $3.01M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.0% | 15,416 | 14,376 | $1.55M |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.6% | 3,755 | 3,567 | $1.37M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.4% | 2,712 | 2,521 | $1.27M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 12,243 | 11,357 | $1.14M |
| G0378 | Hospital observation service, per hour | 1.8% | 18,159 | 8,185 | $969K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.7% | 3,994 | 3,617 | $899K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.0% | 3,363 | 985 | $544K |
271 more codes
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,494 | $489K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,713 | $480K |
| 93971 | <1% | 2,346 | $367K | |
| 72131 | <1% | 920 | $287K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 336 | $279K |
| 93975 | <1% | 1,186 | $269K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 203 | $253K |
| 93970 | <1% | 1,493 | $225K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,425 | $208K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 600 | $189K |
| 72100 | <1% | 1,494 | $154K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 30,675 | $150K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13,391 | $133K |
| 47562 | <1% | 39 | $123K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,338 | $122K |
| 73564 | <1% | 994 | $120K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 172 | $112K |
| 70486 | <1% | 1,596 | $102K | |
| 59025 | Fetal non-stress test | <1% | 663 | $98K |
| 95811 | <1% | 167 | $95K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 70 | $59K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 146 | $56K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,512 | $49K |
| 70496 | <1% | 681 | $47K | |
| 47563 | <1% | 13 | $44K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 26,685 | $44K |
| 93458 | <1% | 31 | $43K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 298 | $36K |
| 12001 | <1% | 1,086 | $28K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 137 | $27K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,756 | $27K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 95 | $25K |
| 74174 | <1% | 39 | $24K | |
| 10060 | <1% | 1,320 | $24K | |
| 93976 | <1% | 3,099 | $24K | |
| 80053 | Comprehensive metabolic panel | <1% | 55,554 | $23K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 33,465 | $21K |
| C1781 | Mesh (implantable) | <1% | 181 | $19K |
| 50590 | <1% | 13 | $19K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,402 | $18K |
| 73130 | <1% | 2,563 | $17K | |
| 71250 | <1% | 232 | $17K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 16,987 | $16K |
| 73630 | <1% | 2,651 | $16K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,993 | $15K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,040 | $14K |
| 73562 | <1% | 2,174 | $14K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 9,534 | $14K |
| 73030 | <1% | 2,533 | $12K | |
| 29580 | <1% | 326 | $11K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 2,273 | $11K |
| 76801 | <1% | 3,105 | $9K | |
| 73110 | <1% | 1,660 | $8K | |
| 96376 | <1% | 7,529 | $8K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,047 | $8K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,215 | $8K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 31,670 | $7K |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | <1% | 85 | $7K |
| 12002 | <1% | 659 | $7K | |
| 73140 | <1% | 513 | $7K | |
| 0042T | <1% | 12 | $6K | |
| 12011 | <1% | 562 | $6K | |
| 88304 | <1% | 1,344 | $6K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,747 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 23,770 | $5K |
| 73610 | <1% | 2,436 | $5K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 8,241 | $5K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 786 | $5K |
| 11043 | <1% | 38 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 354 | $5K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,569 | $4K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 347 | $4K |
| 87400 | <1% | 11,195 | $4K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,254 | $3K |
| 81025 | <1% | 17,357 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 18,149 | $3K |
| 73090 | <1% | 645 | $3K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 67,342 | $3K |
| 73080 | <1% | 782 | $3K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 247 | $3K |
| 71045 | Radiologic examination, chest; single view | <1% | 19,868 | $3K |
| 43249 | <1% | 12 | $2K | |
| 76641 | <1% | 12 | $2K | |
| 76870 | <1% | 163 | $2K | |
| 99292 | <1% | 14 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,076 | $2K |
| 73590 | <1% | 1,000 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 11,620 | $2K |
| 84484 | <1% | 24,496 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,076 | $2K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 204 | $1K |
| J3490 | Unclassified drugs | <1% | 4,777 | $1K |
| 74018 | <1% | 1,656 | $1K | |
| 81001 | <1% | 36,663 | $1K | |
| 87186 | <1% | 5,983 | $1K | |
| 73502 | <1% | 879 | $1K | |
| 70498 | <1% | 680 | $1K | |
| 72128 | <1% | 109 | $1K | |
| 93017 | <1% | 268 | $1K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 9,435 | $1K |
| 93880 | <1% | 100 | $989.43 | |
| 83690 | <1% | 20,570 | $923.14 | |
| 80076 | <1% | 1,350 | $909.74 | |
| 83880 | <1% | 6,809 | $741.50 | |
| 84703 | <1% | 9,106 | $726.10 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,249 | $713.09 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 942 | $694.89 |
| 71101 | <1% | 607 | $688.87 | |
| C1769 | Guide wire | <1% | 1,002 | $685.49 |
| 83735 | <1% | 18,591 | $636.81 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 11,047 | $613.27 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,286 | $604.17 |
| 84702 | <1% | 3,802 | $599.07 | |
| 87088 | <1% | 17,611 | $562.88 | |
| C8923 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, without spectral or color doppler echocardiography | <1% | 59 | $528.73 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 443 | $526.24 |
| 83605 | <1% | 9,341 | $481.22 | |
| 85730 | <1% | 6,746 | $477.41 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,796 | $475.44 |
| 72040 | <1% | 419 | $460.76 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,290 | $437.99 |
| 85379 | <1% | 5,420 | $435.27 | |
| 87081 | <1% | 2,836 | $419.38 | |
| 90715 | <1% | 3,205 | $393.66 | |
| 81003 | <1% | 13,529 | $392.83 | |
| 74019 | <1% | 505 | $390.58 | |
| 82962 | <1% | 19,462 | $373.08 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 25 | $354.08 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 21,460 | $349.02 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 25,562 | $321.47 |
| 80061 | Lipid panel | <1% | 1,891 | $316.13 |
| 29125 | <1% | 1,231 | $303.79 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 14,811 | $301.99 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,470 | $290.10 |
| 73120 | <1% | 98 | $285.45 | |
| 76775 | <1% | 27 | $283.59 | |
| 87040 | <1% | 5,719 | $281.88 | |
| 88342 | <1% | 765 | $276.01 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,412 | $272.79 |
| 97162 | <1% | 155 | $268.80 | |
| 82803 | <1% | 823 | $220.12 | |
| 36600 | <1% | 56 | $219.98 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,057 | $218.53 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 194 | $208.25 |
| 87210 | <1% | 1,980 | $206.28 | |
| 29515 | <1% | 305 | $205.09 | |
| 82550 | <1% | 7,737 | $204.38 | |
| 97163 | <1% | 698 | $193.39 | |
| 85027 | <1% | 6,263 | $187.46 | |
| 85610 | <1% | 10,749 | $186.27 | |
| 87077 | <1% | 4,462 | $167.87 | |
| 97167 | <1% | 254 | $150.41 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,588 | $133.18 |
| 84100 | <1% | 3,468 | $110.43 | |
| 84112 | <1% | 28 | $109.38 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 60 | $96.54 |
| 72070 | <1% | 28 | $92.98 | |
| 86901 | <1% | 4,523 | $92.92 | |
| 29505 | <1% | 190 | $87.89 | |
| 84145 | <1% | 1,261 | $84.26 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,492 | $77.74 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,905 | $74.85 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,560 | $74.61 |
| 73560 | <1% | 15 | $74.05 | |
| 86900 | <1% | 4,521 | $70.60 | |
| 86850 | <1% | 2,170 | $70.14 | |
| 97168 | <1% | 12 | $65.13 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,748 | $62.97 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,031 | $59.06 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 513 | $56.94 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,722 | $51.34 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 225 | $50.58 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 422 | $40.54 |
| 73620 | <1% | 166 | $40.46 | |
| 87147 | <1% | 1,806 | $37.72 | |
| 87070 | <1% | 881 | $36.14 | |
| 87102 | <1% | 178 | $33.93 | |
| 87205 | <1% | 1,073 | $31.44 | |
| 96367 | <1% | 627 | $31.05 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,613 | $23.65 |
| 96368 | <1% | 286 | $22.78 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,269 | $21.71 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 221 | $20.88 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,499 | $18.81 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,236 | $18.20 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,309 | $17.17 |
| J2704 | Injection, propofol, 10 mg | <1% | 9,883 | $16.58 |
| 87420 | <1% | 1,144 | $13.08 | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 143 | $12.50 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 809 | $10.42 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 114 | $10.32 |
| A9270 | Non-covered item or service | <1% | 10,985 | $8.84 |
| 94760 | <1% | 483 | $8.02 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,211 | $7.64 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,665 | $7.51 |
| 99001 | <1% | 401 | $7.26 | |
| 85651 | <1% | 612 | $6.14 | |
| 82270 | <1% | 207 | $4.98 | |
| 76770 | <1% | 27 | $2.90 | |
| 97016 | <1% | 3,071 | $2.26 | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,778 | $1.90 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,636 | $0.60 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,920 | $0.12 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 186 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 1,977 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 141 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 1,014 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 399 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 50 | $0.00 |
| 87899 | 0% | 16 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 216 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 435 | $0.00 |
| 97116 | 0% | 379 | $0.00 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 110 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 433 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 14 | $0.00 |
| 85384 | 0% | 16 | $0.00 | |
| 84439 | 0% | 42 | $0.00 | |
| 87075 | 0% | 113 | $0.00 | |
| 82140 | 0% | 92 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 207 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 201 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 80 | $0.00 |
| 74300 | 0% | 13 | $0.00 | |
| 70360 | 0% | 14 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 54 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 30 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 24 | $0.00 |
| 92610 | 0% | 14 | $0.00 | |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | 0% | 18 | $0.00 |
| S0030 | Injection, metronidazole, 500 mg | 0% | 21 | $0.00 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 14 | $0.00 |
| A9150 | Non-prescription drugs | 0% | 368 | $0.00 |
| 86140 | 0% | 685 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 306 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 359 | $0.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 221 | $0.00 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 92 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 77 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 941 | $0.00 |
| 87116 | 0% | 168 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 261 | $0.00 |
| 74022 | 0% | 385 | $0.00 | |
| 83615 | 0% | 185 | $0.00 | |
| 84132 | 0% | 110 | $0.00 | |
| 90686 | 0% | 155 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 179 | $0.00 |
| J3590 | Unclassified biologics | 0% | 77 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 128 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 12 | $0.00 |
| 82728 | 0% | 35 | $0.00 | |
| 72170 | 0% | 12 | $0.00 | |
| 29130 | 0% | 39 | $0.00 | |
| 87206 | 0% | 168 | $0.00 | |
| 88307 | 0% | 17 | $0.00 | |
| 97166 | 0% | 29 | $0.00 | |
| 73060 | 0% | 39 | $0.00 | |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 43 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 16 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 69 | $0.00 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | 0% | 94 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 43 | $0.00 |
| 73600 | 0% | 18 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 171 | $0.00 |
| 87449 | 0% | 15 | $0.00 | |
| 51798 | 0% | 13 | $0.00 | |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 14 | $0.00 |
| 82746 | 0% | 14 | $0.00 | |
| 86592 | 0% | 33 | $0.00 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 12 | $0.00 |
| 82607 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBLACKWELL, KELSIE (CFO)
| Provider | Location | Paid |
|---|---|---|
| VHS Acquisition Subsidiary Number 1 INC | Phoenix, AZ | $24.35M |
| VHS of Phoenix INC | Mesa, AZ | $1000K |
| VHS Acquisition Subsidiary Number 1 INC | Cave Creek, AZ | $618K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.